[1] CE DeSantis, J Ma, MM Gaudet, LA Newman, KD Miller, SA Goding, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69:438-51.
[2] G Vugts, AJ Maaskant-Braat, GA Nieuwenhuijzen, RM Roumen, EJ Luiten, AC Voogd. Patterns of Care in the Administration of Neo-adjuvant Chemotherapy for Breast Cancer. A Population-Based Study. BREAST J. 2016;22:316-21.
[3] KB Clough, V Acosta-Marin, C Nos, S Alran, P Rouanet, JR Garbay, et al. Rates of Neoadjuvant Chemotherapy and Oncoplastic Surgery for Breast Cancer Surgery: A French National Survey. ANN SURG ONCOL. 2015;22:3504-11.
[4] Mougalian SS, Soulos PR, Killelea BK, Lannin DR, Abu-Khalaf MM, DiGiovanna MP, et al. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer-Am Cancer Soc.2015; 121:2544-52.
[5] S Khokher, S Mahmood, MU Qureshi, SA Khan, NA Chaudhry. "Initial clinical response" to neoadjuvant chemotherapy: an in-vivo chemosensitivity test for efficacy in patients with advanced breast cancer. Asian Pac J Cancer Prev. 2011;12:939-46.
[6] P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino, N Wolmark, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. LANCET. 2014;384:164-72.
[7] LJ Esserman, DA Berry, A DeMichele, L Carey, SE Davis, M Buxton, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J CLIN ONCOL. 2012;30:3242-9.
[8] Pierga JY, Mouret E, Laurence V, Dieras V, Savigioni A, Beuzeboc P, et al. Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response. Eur J Cancer. 2003; 39:1089-1096.
[9] SC Abrial, F Penault-Llorca, R Delva, P Bougnoux, B Leduc, MA Mouret-Reynier, et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat. 2005;94:255-63.
[10] B Fisher, J Bryant, N Wolmark, E Mamounas, A Brown, ER Fisher, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J CLIN ONCOL. 1998;16:2672-85.
[11] WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, et al. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:310-20.
[12] J Zhang, L Xiao, S Pu, Y Liu, J He, K Wang. Can We Reliably Identify the Pathological Outcomes of Neoadjuvant Chemotherapy in Patients with Breast Cancer? Development and Validation of a Logistic Regression Nomogram Based on Preoperative Factors. ANN SURG ONCOL. 2020.
[13] B Ejlertsen, HT Mouridsen, MB Jensen, J Andersen, M Andersson, C Kamby, et al. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. CANCER-AM CANCER SOC. 2010;116:2081-9.
[14] ME Hammond, DF Hayes, AC Wolff, PB Mangu, S Temin. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J ONCOL PRACT. 2010;6:195-7.
[15] A Mrozkowiak, WP Olszewski, A Piascik, WT Olszewski. HER2 status in breast cancer determined by IHC and FISH: comparison of the results. POL J PATHOL. 2004;55:165-71.
[16] CM Perou, T Sorlie, MB Eisen, M van de Rijn, SS Jeffrey, CA Rees, et al. Molecular portraits of human breast tumours. NATURE. 2000;406:747-52.
[17] KN Ogston, ID Miller, S Payne, AW Hutcheon, TK Sarkar, I Smith, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. BREAST. 2003;12:320-7.
[18] WJ YOUDEN. Index for rating diagnostic tests. CANCER-AM CANCER SOC. 1950;3:32-5.
[19] T Uematsu, M Kasami, J Watanabe, K Takahashi, S Yamasaki, K Tanaka, et al. Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer? BREAST CANCER-TOKYO. 2011;18:309-13.
[20] HW Hwang, H Jung, J Hyeon, YH Park, JS Ahn, YH Im, et al. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. Breast Cancer Res Treat. 2019;173:255-66.
[21] R Rouzier, L Pusztai, S Delaloge, AM Gonzalez-Angulo, F Andre, KR Hess, et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J CLIN ONCOL. 2005;23:8331-9.
[22] B Zhou, DQ Yang, F Xie. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma. Chin Med J (Engl). 2008;121:387-91.
[23] J Chang, TJ Powles, DC Allred, SE Ashley, GM Clark, A Makris, et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J CLIN ONCOL. 1999;17:3058-63.
[24] M Colleoni, I Minchella, G Mazzarol, F Nole, G Peruzzotti, A Rocca, et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. ANN ONCOL. 2000;11:1057-9.
[25] PM Ravdin, LA Siminoff, GJ Davis, MB Mercer, J Hewlett, N Gerson, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J CLIN ONCOL. 2001;19:980-91.
[26] AH Lee, SE Pinder, RD Macmillan, M Mitchell, IO Ellis, CW Elston, et al. Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. EUR J CANCER. 2006;42:357-62.
[27] N Tamura, T Hasebe, N Okada, T Houjoh, S Akashi-Tanaka, C Shimizu, et al. Tumor histology in lymph vessels and lymph nodes for the accurate prediction of outcome among breast cancer patients treated with neoadjuvant chemotherapy. CANCER SCI. 2009;100:1823-33.
[28] T Uematsu, M Kasami, J Watanabe, K Takahashi, S Yamasaki, K Tanaka, et al. Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer? BREAST CANCER-TOKYO. 2011;18:309-13.
[29] PS Sullivan, SK Apple. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma? BREAST J. 2009;15:146-54.
[30] JJ Caro, M Salas, A Ward, G Goss. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. CANCER-AM CANCER SOC. 2001;91:2214-21.
[31] DU Boehm, A Lebrecht, M Schmidt, W Siggelkow, C Lindner, A Litz, et al. Prognostic impact of haemoglobin levels in breast cancer. ANTICANCER RES. 2007;27:1223-6.
[32] P Vaupel, O Thews, M Hoeckel. Treatment resistance of solid tumors: role of hypoxia and anemia. MED ONCOL. 2001;18:243-59.
[33] P Dubsky, P Sevelda, R Jakesz, H Hausmaninger, H Samonigg, M Seifert, et al. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. CLIN CANCER RES. 2008;14:2082-7.
[34] A Bottini, A Berruti, MP Brizzi, A Bersiga, D Generali, G Allevi, et al. Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer. Br J Cancer. 2003;89:977-82.
[35] E Alba, J Albanell, J de la Haba, A Barnadas, L Calvo, P Sanchez-Rovira, et al. Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. Br J Cancer. 2014;110:1139-47.
[36] LJ Esserman, DA Berry, A DeMichele, L Carey, SE Davis, M Buxton, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J CLIN ONCOL. 2012;30:3242-9.
[37] M Stendahl, L Ryden, B Nordenskjold, PE Jonsson, G Landberg, K Jirstrom. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. CLIN CANCER RES. 2006;12:4614-8.
[38] A Tordai, J Wang, F Andre, C Liedtke, K Yan, C Sotiriou, et al. Evaluation of biological pathways involved in chemotherapy response in breast cancer. BREAST CANCER RES. 2008;10:R37.
[39] J Hugh, J Hanson, MC Cheang, TO Nielsen, CM Perou, C Dumontet, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J CLIN ONCOL. 2009;27:1168-76.
[40] C Denkert, S Loibl, BM Muller, H Eidtmann, WD Schmitt, W Eiermann, et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. ANN ONCOL. 2013;24:2786-93.
[41] L Gianni, W Eiermann, V Semiglazov, A Manikhas, A Lluch, S Tjulandin, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. LANCET. 2010;375:377-84.
[42] I Echavarria, M Granja, C Bueno, S Lopez-Tarruella, P Peinado, M Sotelo, et al. Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer. Breast Cancer Res Treat. 2017;162:181-9.
[43] MJ Piccart-Gebhart, M Procter, B Leyland-Jones, A Goldhirsch, M Untch, I Smith, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-72.
[44] EH Romond, EA Perez, J Bryant, VJ Suman, CJ Geyer, NE Davidson, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-84.
[45] D Slamon, W Eiermann, N Robert, T Pienkowski, M Martin, M Press, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273-83.
[46] F Cardoso, A Costa, E Senkus, M Aapro, F Andre, CH Barrios, et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). ANN ONCOL. 2017;28:16-33.
[47] E Senkus, S Kyriakides, S Ohno, F Penault-Llorca, P Poortmans, E Rutgers, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANN ONCOL. 2015;26 Suppl 5:v8-30.